Ajanta Pharma Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

1,421.64

1,374.84

1,353.73

1,302.65

1,170.41

1,146.13

1,186.64

Other Operating Income

0.00

Total Operating income

1,421.64

1,374.84

1,353.73

1,302.65

1,170.41

1,146.13

1,186.64

Raw Material Cost

256.76

235.07

217.60

207.08

190.96

210.14

207.09

Purchase of Finished goods

71.35

53.55

53.26

51.63

80.18

78.55

45.79

(Increase) / Decrease In Stocks

-23.30

-2.36

45.95

17.17

12.28

-30.88

8.80

Employee Cost

340.72

330.52

317.01

302.90

279.78

265.17

260.96

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

442.70

375.82

392.08

372.52

310.06

302.32

352.83

Total Expenditure (Excl Depreciation)

1,088.23

992.60

1,025.90

951.30

873.26

825.30

875.47

Operating Profit (PBDIT) excl Other Income

333.41

382.24

327.83

351.35

297.15

320.83

311.17

Other Income

61.43

24.97

59.34

26.33

18.11

30.44

19.48

Operating Profit (PBDIT)

394.84

407.21

387.17

377.68

315.26

351.27

330.65

Interest

2.36

5.10

3.39

5.26

6.07

7.91

6.02

Exceptional Items

0.00

Gross Profit (PBDT)

392.48

402.11

383.78

372.42

309.19

343.36

324.63

Depreciation

45.37

43.51

42.97

41.29

39.78

35.97

34.39

Profit Before Tax

347.11

358.60

340.81

331.13

269.41

307.39

290.24

Tax

80.41

84.83

80.62

75.79

44.15

74.51

73.76

Provisions and contingencies

0.00

Profit After Tax

266.70

273.77

260.19

255.34

225.26

232.88

216.48

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

266.70

273.77

260.19

255.34

225.26

232.88

216.48

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

266.70

273.77

260.19

255.34

225.26

232.88

216.48

Equity Capital

25.07

Face Value

2.0

Reserves

0.00

Earnings per share (EPS)

21.28

21.84

20.76

20.37

17.97

18.58

17.27

Diluted Earnings per share

21.34

21.91

20.82

20.43

18.0

18.59

17.26

Operating Profit Margin (Excl OI)

23.45%

27.8%

24.22%

26.97%

25.39%

27.99%

26.22%

Gross Profit Margin

27.61%

29.25%

28.35%

28.59%

26.42%

29.96%

27.36%

PAT Margin

18.76%

19.91%

19.22%

19.6%

19.25%

20.32%

18.24%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Mar 2026 is 21.47% vs 11.04% in Mar 2025

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is 18.40% vs 11.12% in Mar 2025

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 12.20% vs 6.77% in Mar 2025

Interest

YoY Growth in quarter ended Mar 2026 is -61.12% vs 296.73% in Mar 2025

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025

Compare Quarterly Results Of Ajanta Pharma With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

1,421.64

2,392.50

-970.86

-40.58%

Other Operating Income

0.00

Total Operating income

1,421.64

2,392.50

-970.86

-40.58%

Raw Material Cost

256.76

564.44

-307.68

-54.51%

Purchase of Finished goods

71.35

129.83

-58.48

-45.04%

(Increase) / Decrease In Stocks

-23.30

-36.37

13.07

35.94%

Employee Cost

340.72

546.09

-205.37

-37.61%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

442.70

655.16

-212.46

-32.43%

Total Expenditure (Excl Depreciation)

1,088.23

1,859.15

-770.92

-41.47%

Operating Profit (PBDIT) excl Other Income

333.41

533.35

-199.94

-37.49%

Other Income

61.43

20.19

41.24

204.26%

Operating Profit (PBDIT)

394.84

553.54

-158.70

-28.67%

Interest

2.36

17.62

-15.26

-86.61%

Exceptional Items

0.00

17.65

-17.65

-100.00%

Gross Profit (PBDT)

392.48

553.57

-161.09

-29.10%

Depreciation

45.37

107.59

-62.22

-57.83%

Profit Before Tax

347.11

445.98

-98.87

-22.17%

Tax

80.41

81.93

-1.52

-1.86%

Provisions and contingencies

0.00

Profit After Tax

266.70

364.05

-97.35

-26.74%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

266.70

364.05

-97.35

-26.74%

Share in Profit of Associates

0.00

-0.38

0.38

100.00%

Minority Interest

0.00

37.40

-37.40

-100.00%

Other related items

0.00

Consolidated Net Profit

266.70

326.27

-59.57

-18.26%

Equity Capital

25.07

25.37

-0.30

-1.18%

Face Value

2.00

1.00

0.00

Reserves

0.00

Earnings per share (EPS)

21.28

12.86

8.42

65.47%

Diluted Earnings per share

21.34

12.86

8.48

65.94%

Operating Profit Margin (Excl OI)

23.45%

22.29%

0.00

1.16%

Gross Profit Margin

27.61%

23.14%

0.00

4.47%

PAT Margin

18.76%

15.22%

0.00

3.54%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 1,421.64 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 3.40% vs 1.56% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 21.47% vs 11.04% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 266.70 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -2.58% vs 5.22% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 18.40% vs 11.12% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 333.41 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -12.77% vs 16.60% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 12.20% vs 6.77% in Mar 2025

Quarterly - Interest

Interest 2.36 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -53.73% vs 50.44% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -61.12% vs 296.73% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 23.45%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025